SEC For	rm 4																			
FORM 4 UNITED STAT					TES	TES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549											OMB APPROVAL			
Section 16. Form 4 or Form 5 obligations may continue. See						IT OF CHANGES IN BENEFICIAL OWNERS pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940										Estim		er: verage burde sponse:	3235-0287 n 0.5	
1. Name and Address of Reporting Person* <u>MOLLOY ANTHONY</u>						2. Issuer Name and Ticker or Trading Symbol <u>Pacira BioSciences, Inc.</u> [PCRX]									neck all appli Directe	cable)	ive title C		to Issuer % Owner her (specify	
 (Last) (First) (Middle) C/O PACIRA BIOSCIENCES, INC. 5401 WEST KENNEDY BOULEVARD, SUITE 890 						3. Date of Earliest Transaction (Month/Day/Year) 01/04/2022									A below) below) Chief Lgl & Compliance Officer					
(Street) TAMPA FL 33609			33609	609			4. If Amendment, Date of 0				of Original Filed (Month/Day/Year)				ndividual or Joint/Group Filing (Check Applicable e) X Form filed by One Reporting Person Form filed by More than One Reporting Person				m	
(City) (State) (Zip)																				
		Tab	le I - Noi	ו-Deriv	ative	e Se	curities	s Ac	quired,	Dis	posed o	of, o	r Bei	neficia	lly Owned	b				
1. Title of Security (Instr. 3) 2. Transa Date (Month/D					Execution D			Code (Instr.						Benefici	s Form ally (D) c following (I) (II		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership		
									Code	v	Amount		(A) or (D)	Price	Transac (Instr. 3	tion(s)			(Instr. 4)	
Common Stock 01/04/					/2022	2022		Α		2,000	2,000 ⁽¹⁾ A		\$0.0	0 17,774 ⁽²⁾			D			
		т							uired, D 5, option						y Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execution Date, if any		Transaction Code (Instr.)		of I		6. Date Exe Expiration (Month/Day		Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)		Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
														Amount or						

 Option (Right to Buy)
 \$61.6
 01/04/2022

Explanation of Responses:

1. Represents restricted stock units that vest in four equal annual installments beginning on January 2, 2023, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.

Date Exercisable

(3)

Expiration Date

01/04/2032

Title

Common Stock

2. Includes 224 shares of common stock acquired under the issuer's employee stock purchase plan in December 2021.

3. The stock option vests and becomes exercisable as to 25% of the option shares on December 7, 2022, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.

Remarks:

Stock

<u>/s/ Kristen Williams, Attorney-</u> <u>in-Fact</u> <u>01/10/2022</u>

\$<mark>0.00</mark>

5,000

D

raci

** Signature of Reporting Person Date

of Shares

5,000

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Code V

A

(A)

5,000

(D)

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.